Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Azithromycin to infants

Phase 3Small molecule

UUniversity of Maryland, Baltimore

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stillbirths and Infant MortalityActive, not recruiting

Stillbirths and Infant MortalityPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q1 2027

ApprovedActive, not recruiting

Stillbirths and Infant Mortality

NCT03909737

Clinical

Trials by Indication[1]

Stillbirths and Infant Mortality1 trial

Sauver Avec l'Azithromycine en Traitant Les Femmes Enceintes et Les Enfants (SANTE)

Active, not recruiting·UUniversity of Maryland, Baltimore·Approved·NCT03909737·99,700 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azithromycin to infants. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azithromycin to infants compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azithromycin to infants. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Related News